Concepedia

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

Sotirios Tsimikas, Nicholas J. Viney, Steven G. Hughes, W. S. Singleton, Mark J. Graham, Brenda F. Baker, Jennifer Burkey, Qingqing Yang, Santica M. Marcovina, Richard S. Geary,

The Lancet · 2015 · 464 citations · 26 references

DOI

Concepts

References

26

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

New England Journal of Medicine · 2014 · 1.7K citations · Full text

, , +17

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

Robert Clarke, John F. Peden, Jemma C. Hopewell et al. · New England Journal of Medicine · 2009 · 1.6K citations · Full text

, , +17

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

Pia R. Kamstrup · JAMA · 2009 · 1.3K citations

, , +16

Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease

Sotirios Tsimikas, Emmanouil S. Brilakis, Elizabeth R. Miller et al. · New England Journal of Medicine · 2005 · 768 citations · Full text

, , +16

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

Harry R. Büller, Claudette Bethune, Sanjay Bhanot et al. · New England Journal of Medicine · 2014 · 622 citations · Full text

, , +11